Home > Products > CD89 & EGFR > Recombinant Human Anti-CD89 x Anti-EGFR Bispecific Antibody (Tandem scFv)

Recombinant Human Anti-CD89 x Anti-EGFR Bispecific Antibody (Tandem scFv)  (CAT#: BSFV-H303)

Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-CD89 antibody variable domains fused with a scFv from an anti-EGFR antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
Datasheet INQUIRY

Specifications

Targets
CD89 & EGFR
Type
Tandem scFv
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC)Solid tumors

Targets

Target 1
CD89
Gene ID
UniProt ID
Alternative Names
FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor
Target 2
EGFR
Gene ID
UniProt ID
Alternative Names
EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD89 & EGFR"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD89 x Anti-EGFR Bispecific Antibody (Tandem scFv) (BSFV-H303). Click the button below to contact us or submit your feedback about this product.